



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Stelara

Page:

1 of 8

Effective Date: 4/9/2025

Last Review Date: 12/2023;
4/2024;
2/2025

Applies
to:

☐ Illinois

☒ New Jersey

☐ Pennsylvania Kids

☐ Florida

☐ Maryland

☐ Virginia

☐ Florida Kids

☐ Michigan

☐ Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Stelara under the patient's prescription drug benefit.

Description:

A. FDA-Approved Indications

1. Moderate to severe plaque psoriasis (PsO) in patients 6 years or older who are candidates for phototherapy or systemic therapy (Reference the Biological Response Modifiers (BRMs) in the Treatment of Plaque Psoriasis NJ Protocol)
2. Active psoriatic arthritis (PsA) in patients 6 years or older
3. Moderately to severely active Crohn's disease (CD) in adults
4. Moderately to severely active ulcerative colitis (UC) in adults

B. Compendial Uses

Immune checkpoint inhibitor-related toxicity

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:


Non-preferred:

Stelara (ustekinumab)
Imuldosa (ustekinumab-srlf)
Otulfi (ustekinumab-aaaz)
Pyzchiva (ustekinumab-ttwe)
Selarsdi (ustekinumab-aekn)
Steqeyma (ustekinumab-stba)
Wezlana (ustekinumab-auub)
Yesintek (ustekinumab-kfce)
ustekinumab-aekn (unbranded Selarsdi)

Policy/Guideline:

Documentation for all indications:

The patient is unable to take TWO preferred products (a preferred adalimumab product, Enbrel, Otezla or Rinvoq), where indicated, for the given diagnosis due to a trial and

	
AETNA BETTER HEALTH® Coverage Policy/Guideline	
Name: Stelara	Page: 2 of 8
Effective Date: 4/9/2025	Last Review Date: 12/2023; 4/2024; 2/2025
Applies to:	<input type="checkbox"/> Illinois <input checked="" type="checkbox"/> New Jersey <input type="checkbox"/> Pennsylvania Kids
	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia
	<input type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Kentucky PRMD

inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

Documentation:

- A. **Psoriatic arthritis**
 - 1. Initial requests: Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.
 - 2. Continuation requests: Chart notes or medical record documentation supporting positive clinical response.

- B. **Crohn’s disease**
Continuation requests: Chart notes or medical record documentation supporting positive clinical response to therapy or remission.

- C. **Ulcerative colitis**
Continuation requests: Chart notes or medical record documentation supporting positive clinical response to therapy or remission.

- D. **Immune checkpoint inhibitor-related toxicity**
Chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy or intolerance to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.

- Prescriber Specialty:**
The medication must be prescribed by or in consultation with one of the following:
- A. Psoriatic arthritis: rheumatologist or dermatologist
 - B. Crohn’s disease and ulcerative colitis: gastroenterologist
 - C. Immune checkpoint inhibitor-related toxicity: gastroenterologist, hematologist or oncologist

Criteria for Initial Approval:

A. Psoriatic arthritis (PsA)



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Stelara	Page:	3 of 8
Effective Date:	4/9/2025	Last Review Date:	12/2023; 4/2024; 2/2025
Applies to:	<input type="checkbox"/> Illinois <input checked="" type="checkbox"/> New Jersey <input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Kentucky PRMD

1. Authorization of 12 months may be granted for members 6 years of age or older who have previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis.
2. Authorization of 12 months may be granted for members 6 years of age or older for treatment of active psoriatic arthritis when either of the following criteria is met:
 - i. Member has mild to moderate disease and meets one of the following criteria:
 - a. Member has had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine) administered at an adequate dose and duration.
 - b. Member has an intolerance or contraindication to methotrexate or leflunomide (see Appendix), or another conventional synthetic drug (e.g., sulfasalazine).
 - c. Member has enthesitis
 - ii. Member has severe disease.

B. Crohn's disease (CD)

Authorization of 12 months may be granted for adult members for treatment of moderately to severely active Crohn's disease.

C. Ulcerative colitis (UC)

Authorization of 12 months may be granted for adult members for treatment of moderately to severely active ulcerative colitis.

D. Immune checkpoint inhibitor-related toxicity

Authorization of 6 months may be granted for the treatment of immune checkpoint inhibitor-related diarrhea or colitis when the member has experienced an inadequate response, intolerance, or contraindication to infliximab or vedolizumab.

Continuation of Therapy:

A. Psoriatic arthritis (PsA)

Authorization of 12 months may be granted for all members 6 years of age or older (including new members) who are using the requested medication for psoriatic arthritis and who achieve or maintain positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Stelara

Page: 4 of 8

Effective Date: 4/9/2025

12/2023;
Last Review Date: 4/2024;
2/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

1. Number of swollen joints
2. Number of tender joints
3. Dactylitis
4. Enthesitis
5. Skin and/or nail involvement
6. Functional status
7. C-reactive protein (CRP)

B. Crohn's Disease (CD)

1. Authorization of 12 months may be granted for all adult members (including new members) who are using the requested medication for moderately to severely active or fistulizing Crohn's disease and who achieve or maintain remission.
2. Authorization of 12 months may be granted for all adult members (including new members) who are using the requested medication for moderately to severely active or fistulizing Crohn's disease and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:
 - i. Abdominal pain or tenderness
 - ii. Diarrhea
 - iii. Body weight
 - iv. Abdominal mass
 - v. Hematocrit
 - vi. Endoscopic appearance of the mucosa
 - vii. Improvement on a disease activity scoring tool (e.g., Crohn's Disease Activity Index [CDAI] score)

C. Ulcerative colitis

1. Authorization of 12 months may be granted for all adult members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain remission.
2. Authorization of 12 months may be granted for all adult members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Stelara

Page:

5 of 8

Effective Date: 4/9/2025

Last Review Date: 12/2023;
4/2024;
2/2025

Applies
to:

☐ Illinois

☒ New Jersey

☐ Pennsylvania Kids

☐ Florida

☐ Maryland

☐ Virginia

☐ Florida Kids

☐ Michigan

☐ Kentucky PRMD

- i. Stool frequency
- ii. Rectal bleeding
- iii. Urgency of defecation
- iv. C-reactive protein (CRP)
- v. Fecal calprotectin (FC)
- vi. Endoscopic appearance of the mucosa
- vii. Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo score)

D. Immune checkpoint inhibitor-related toxicity

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

Other Criteria:

For all indications: Member has had a documented negative tuberculosis (TB) test (which can include a tuberculosis skin test [TST] or an interferon-release assay [IGRA]) within 12 months of initiating therapy for persons who are naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of TB.

If the screening testing for TB is positive, there must be further testing to confirm there is no active disease (e.g., chest x-ray). Do not administer the requested medication to members with active TB infection. If there is latent disease, TB treatment must be started before initiation of the requested medication.

For all indications: Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

Dosage and Administration:

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Appendix

Examples of Clinical Reasons to Avoid Pharmacologic Treatment with Methotrexate, Cyclosporine, Acitretin, or Leflunomide

1. Clinical diagnosis of alcohol use disorder, alcoholic liver disease, or other chronic liver disease
2. Drug interaction
3. Risk of treatment-related toxicity



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Stelara

Page:

6 of 8

Effective Date: 4/9/2025

Last Review Date: 12/2023;
4/2024;
2/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

4. Pregnancy or currently planning pregnancy
5. Breastfeeding
6. Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension)
7. Hypersensitivity
8. History of intolerance or adverse event

Approval Duration and Quantity Restrictions:

Approval:

Initial Approval:

- 6 months for Immune checkpoint inhibitor-related toxicity
- 12 months for all other indications

Renewal Approval:

- 6 months for Immune checkpoint inhibitor-related toxicity
- 12 months for all other indications

Quantity Level Limit:

Stelara 130 mg/26 mL single-dose vial:

- Standard Limit: 4 vials (1 dose)

Stelara subcutaneous injection 45 mg/0.5 mL single-dose vial/prefilled syringe:

- Standard Limit: 1 vial/syringe per 84 days
- Exception Limit: 2 vials/syringes per 28 days*

Stelara (ustekinumab) subcutaneous injection 90 mg/mL prefilled syringe:

- Standard Limit: 1 syringe per 56 days
- Exception Limit: 2 syringes per 28 days*

FDA-Recommended Dosing:

CD, UC intravenous induction

- ≤ 55 kg: 260 mg (2 vials)
- > 55 kg to 85 kg: 390 mg (3 vials)
- > 85 kg: 520 mg (4 vials)



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Stelara	Page:	7 of 8
Effective Date:	4/9/2025	Last Review Date:	12/2023; 4/2024; 2/2025
Applies to:	<input type="checkbox"/> Illinois <input checked="" type="checkbox"/> New Jersey <input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Kentucky PRMD

PsO, adult

- ≤ 100 kg: 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks
- > 100 kg: 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks

PsO, pediatric (6-17 years old): Weight based dosing at the initial dose, 4 weeks later, and then every 12 weeks thereafter

- < 60 kg: 0.75 mg/kg
- 60 kg to 100 kg: 45 mg
- > 100 kg: 90 mg

PsA, adult

- 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks
- > 100 kg with co-existent PsO: 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks

PsA, pediatric (6-17 years old): Weight based dosing at the initial dose, 4 weeks later, and then every 12 weeks there after

- < 60 kg: 0.75 mg/kg
- 60 kg or more: 45 mg
- > 100 kg with co-existent PsO: 90 mg

CD, UC maintenance dose

- 90 mg 8 weeks after the initial intravenous dose, then every 8 weeks thereafter

*Coverage up to the exception limits may be provided with prior authorization

References:

1. Stelara [package insert]. Horsham, PA: Janssen Biotech, Inc.; March 2024.
2. Imuldosa [package insert]. Raleigh, NC: Accord BioPharma Inc.; October 2024.
3. Otulfi [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; September 2024.
4. Pyzchiva [package insert]. Incheon, Republic of Korea: Samsung Bioepis Co., Ltd.; June 2024.
5. Selarsdi [package insert]. Leesburg, VA: Alvotech USA Inc.; April 2024.
6. Steqeyma [package insert]. Jersey City, NJ: Celltrion USA, Inc.; December 2024.
7. ustekinumab-aekn [package insert]. Leesburg, VA: Alvotech USA Inc.; October 2024.
8. Wezlana [package insert]. Thousand Oaks, CA: Amgen Inc.; October 2023.
9. Yesintek [package insert]. Cambridge, MA: Biocon Biologics Inc.; November 2024.
10. Menter A, Korman NJ, Elmetts CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-174.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Stelara	Page:	8 of 8
Effective Date:	4/9/2025	Last Review Date:	12/2023; 4/2024; 2/2025
Applies to:	<input type="checkbox"/> Illinois <input checked="" type="checkbox"/> New Jersey <input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Kentucky PRMD

11. Gossec L, Baraliakos X, Kerschbaumer A, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*. 2020;79(6):700-712.
12. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis* 2005;64(Suppl II):ii14–ii17.
13. Talley NJ, Abreu MT, Achkar J, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. *Am J Gastroenterol*. 2011;106(Suppl 1):S2-S25.
14. Lichtenstein GR, Loftus Jr EV, Isaacs KI, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113:481-517.
15. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072.
16. Testing for TB Infection. Centers for Disease Control and Prevention. Retrieved on January 5, 2024 from: <https://www.cdc.gov/tb/topic/basics/risk.htm>.
17. Talley NJ, Abreu MT, Achkar J, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. *Am J Gastroenterol*. 2011;106(Suppl 1):S2-S25.
18. Rubin DT, Ananthakrishnan AN, et al. 2019 ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol*. 2019;114:384-413.
19. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology*. 2020; 158:1450.
20. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheumatol*. 2019;71(1):5-32. doi:10.1002/art.40726.
21. Menter A, Cordero KM, Davis DM, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis in pediatric patients. *J Am Acad Dermatol*. 2020;82(1):161-201.
22. Menter A, Gelfand JM, Connor C, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6): 1445-86.
23. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology*. 2021; 160: 2496-2508.
24. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed January 15, 2024.
25. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. *Nat Rev Rheumatol*. 2022;18(8):465-479.
26. NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®). Management of Immunotherapy-Related Toxicities. Version 1.2024. Available at: www.nccn.org. Accessed January 15, 2024.